Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Sino Biopharmaceutical (SBMFF) Consolidated Net Income/Loss data is not available for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Consolidated Net Income/Loss |
-- |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$4.67B |
|
$1.17B |
|
$5.68B |
|
$10.35B |
|
$3.43B |
|
$414.52M |
|
$589.57M |
|
$4.02B |
|
$6.33B |
|
$5.90B |
|
$6.33B |
|
18.76B |
|
| Cash Flow Statement Financials | |
$436.77M |
|
$-1.01B |
|
$217.94M |
|
$861.20M |
|
$504.52M |
|
$-356.67M |
|
-- |
|
$-3.58M |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|